UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/579,042	01/30/2007	Koo Lee	1599-0325PUS1	6361	
	7590 04/12/201 ART KOLASCH & BI		EXAMINER		
PO BOX 747	CH 3/A 22040 0747	BASQUILL, SEAN M			
FALLS CHURG	FALLS CHURCH, VA 22040-0747 ART UNIT PA		PAPER NUMBER		
			1612		
			NOTIFICATION DATE	DELIVERY MODE	
			04/12/2010	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

	Application No.	Applicant(s)			
Office Action Commence	10/579,042	LEE ET AL.			
Office Action Summary	Examiner	Art Unit			
	Sean Basquill	1612			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	s		
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period versiling to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I. lely filed the mailing date of this commun (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on					
	action is non-final.				
3) Since this application is in condition for allowar		secution as to the mer	rits is		
closed in accordance with the practice under E					
·	,				
Disposition of Claims					
4)⊠ Claim(s) <u>1-20</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdraw	vn from consideration.				
5) Claim(s) is/are allowed.					
6)☐ Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8)⊠ Claim(s) <u>1-20</u> are subject to restriction and/or €	election requirement.				
Application Papers					
9) The specification is objected to by the Examine	r.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correct	ion is required if the drawing(s) is obj	ected to. See 37 CFR 1.	121(d).		
11)☐ The oath or declaration is objected to by the Ex					
Priority under 35 U.S.C. § 119					
12) ☐ Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)	-(d) or (f).			
a) ☐ All b) ☐ Some * c) ☐ None of:	p. 10.13	(4) 4. (.).			
1.☐ Certified copies of the priority documents	s have been received				
2. ☐ Certified copies of the priority documents		on No			
	• •	<u> </u>	Δ.		
	3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).				
* See the attached detailed Office action for a list of the certified copies not received.					
Gee the attached detailed Office action for a list	or the certified copies not receive	u.			
Attachmont(a)					
Attachment(s) 1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO-413)			
Notice of References Cited (PTO-992) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da				
3) Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal P	atent Application			
Paper No(s)/Mail Date	6) [Other:				

Application/Control Number: 10/579,042 Page 2

Art Unit: 1612

DETAILED ACTION

Restriction Requirement

- 1. Restriction is required under 35 U.S.C. 121 and 372. This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.
 - Group I, claims 1-16 drawn to azetidine compounds;
 - Group II, claims 1-16 drawn to pyrrolidine compounds;
 - Group III, claims 1-16, drawn to piperidine compounds;
 - Group IV, claim 17, drawn to methods of treating obesity;
 - Group V, claim 18, drawn to methods of treating diabetes;
 - Group VI, claim 19, drawn to methods of treating inflammation;
 - Group VII, claim 20, drawn to methods of treating erectile dysfunction.

As set forth in Rule 13.1 of the Patent Cooperation Treaty (PCT), "the international application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept." Moreover, as stated in PCT Rule 13.2, "where a group of inventions is claimed in one and the same international application, the requirement of unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features."

Furthermore, Rule 13.2 defines "special technical features" as "those technical features that

Art Unit: 1612

define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art."

2. The inventions listed as Groups I-VII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Group I is a compound of Formula 1. Claim 1 is directed to multiple patentably distinct inventions, NOT species. Each of the specifically claimed core compounds encompassed by Formula 1, wherein n and m are each independently selected from one or two carbon atoms, lack unity of invention because the compounds have no substantial structural similarities although they have a common utility, . *In re Harnisch*, 631 F.2d 716, 206 USPQ 300(CCPA 1980); and *Ex parte Hozumi*, 3 USPQ2d 1059 (Bd. Pat. App. & Int. 1984). For example, a compound of Formula 1, wherein n and m are each one carbon (describing an azetidine core) is structurally distinct from a compound of Formula 1, wherein n and m are each two carbon atoms (describing a piperidine core), or either n is one carbon and m is two carbon atoms, or vice-versa (describing pyrrolidine cores).

Thus, Applicant is advised that a reply to this requirement must include an identification of the invention, *e.g.* a selection of values for n and m in the claimed compound of formula 1, that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Application/Control Number: 10/579,042

Page 4

Art Unit: 1612

In summary, applicant should elect ONE COMMON CORE of the compound of formula

1. Applicant should note that selection of ONE COMMON CORE is for RESTRICTION

purposes, to limit the application to ONE INVENTION. Once a common core has been elected,

applicant will be further required to provide a species election of one specific chemical

compound having that core for purposes of focusing the examiner's search for art pertinent to the

applicants invention.

3. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. <u>All</u> claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained.

Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be

Application/Control Number: 10/579,042

Art Unit: 1612

amended during prosecution to require the limitations of the product claims. **Failure to do so**may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Page 5

Election of Species

4. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

If Group I is elected, the following species election is required:

a. A single compound of formula 1.

If Group II is elected, the following species election is required:

b. A single compound of formula 1.

If Group III is elected, the following species election is required:

c. A single compound of formula 1.

If Group IIV is elected, the following species election is required:

d. A single compound of formula 1.

If Group V is elected, the following species election is required:

e. A single compound of formula 1.

If Group VI is elected, the following species election is required:

f. A single compound of formula 1.

Page 6

If Group VII is elected, the following species election is required:

g. A single compound of formula 1.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. Specifically, Applicant is required to define each of R¹-R⁵, and if necessary owing to the election of substituents R¹-R⁵, the identity of any substituents R⁶-R¹⁰ as well as any additional variables as required to clearly and distinctly describe a particular species of the compound of formula 1 Applicants are reminded that a species for example is methyl, NOT a generic phrase directed to "alkyl" substituents. Upon Applicant's election of species, the result must provide a single chemical species of the compound of Formula 1. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

There is an examination and search burden for these patentably distinct species due to their mutually exclusive characteristics. The species require a different field of search (e.g., searching different classes/subclasses or electronic resources, or employing different search queries); and/or the prior art applicable to one species would not likely be applicable to another

Art Unit: 1612

species; and/or the species are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

The election of the species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the election of species requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected species.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the species unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other species.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141.

Page 8

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Sean Basquill whose telephone number is (571) 270-5862. The

examiner can normally be reached on Monday through Friday, between 8AM and 5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Frederick Krass can be reached on (571) 272-0580. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Sean Basquill

Art Unit 1612

/Jeffrey S. Lundgren/

Primary Examiner, Art Unit 1639